Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 11391682)

  • 1. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
    Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
    Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.
    Fixemer T; Remberger K; Bonkhoff H
    Prostate; 2002 Oct; 53(2):118-23. PubMed ID: 12242726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
    Puccetti L; Supuran CT; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S; Mandras R; Milazzo MG; Dogliani N; De Giuli P; Fasolis G
    Eur Urol; 2005 Aug; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.
    Bonkhoff H
    Prostate Suppl; 1998; 8():18-22. PubMed ID: 9690659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine differentiation in the progression of prostate cancer.
    Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
    Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.
    Kishi H; Igawa M; Kikuno N; Yoshino T; Urakami S; Shiina H
    J Urol; 2004 May; 171(5):1855-60. PubMed ID: 15076293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
    Cox ME; Deeble PD; Lakhani S; Parsons SJ
    Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin expression and its relationship with apoptosis and prognosis in nasal and paranasal sinus carcinomas.
    Zhang Y; Huang D; Yu G
    Acta Otolaryngol; 2005 Dec; 125(12):1345-50. PubMed ID: 16303685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
    Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
    Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
    J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
    Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
    Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
    Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
    Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells.
    Untergasser G; Plas E; Pfister G; Heinrich E; Berger P
    Prostate; 2005 Sep; 64(4):419-29. PubMed ID: 15800938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptors for BPH growth factors are located in some neuroendocrine cells.
    Iwamura M; Koshiba K; Cockett AT
    Prostate Suppl; 1998; 8():14-7. PubMed ID: 9690658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.